Enhanced effectiveness of last generation antiblastic compounds vs. cisplatin on malignant pleural mesothelioma cell lines

European Journal of Pharmacology

Volumn 473, Issue 2-3, 2003, Pages 83-95

  De Cupis, Alessandra ^a   Semino, Claudia ^a   Pirani, Paolo ^a   Loprevite, Maura ^a   Ardizzoni, Andrea ^a   Favoni, Roberto E ^a  

^a UNIVERSITY OF GENOA   (Italy)

Author keywords

Antiproliferative activity; Apoptosis; Experimental therapeutics; Malignant mesothelioma

Indexed keywords

7 ETHYL 10 HYDROXYCAMPTOTHECIN; ANTIBLASTIC COMPOUND; ANTINEOPLASTIC AGENT; CISPLATIN; DNA; DOCETAXEL; FENRETINIDE; GEMCITABINE; IRINOTECAN; PACLITAXEL; RETINOIC ACID DERIVATIVE; TOPOTECAN; UNCLASSIFIED DRUG;

ADULT; AGED; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CELL PROLIFERATION; CELL STRUCTURE; CHEMOSENSITIVITY; COLORIMETRY; CONTROLLED STUDY; CYTOTOXICITY; DNA CONTENT; DNA DETERMINATION; DRUG ACTIVITY; DRUG EFFECT; DRUG EFFICACY; DRUG SCREENING; EVALUATION; EXPERIMENTAL MODEL; FEMALE; HUMAN; HUMAN CELL; IN VITRO STUDY; INHIBITION KINETICS; MALE; MOLECULE; PLEURA EFFUSION; PLEURA MESOTHELIOMA; PRIORITY JOURNAL; REPRODUCIBILITY; SAMPLE; STRUCTURE ANALYSIS; TREATMENT INDICATION; TUMOR BIOPSY;

EID: 0043209011     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0014-2999(03)01907-1     Document Type: Article

References (62)

1. Aisner J. Current approach to malignant mesothelioma of the pleura. Chest. 107:1995;332S-344S.
2. Ardizzoni A., Rosso R., Salvati F., Fusco V., Cinquegrana A., De Palma M., Serrano J., Pennucci M.C., Soresi E., Crippa M. Activity of doxorubicin and cisplatinplatin combination chemotherapy in patients with diffuse malignant mesothelioma. Cancer. 67:1991;2984-2987.
3. Baas P. Chemotherapy for malignant mesothelioma: from doxorubicin to vinorelbine. Semin. Oncol. 29(1):2002;62-69.
4. Bischoff H., Manegold C., Knopp M., Blatter J., Drings P. Gemcitabine may reduce tumour load and tumour associated symptoms in malignant mesothelioma. Proc. Am. Soc. Clin. Oncol. 17:1998;A1784.
5. Bowman R.V., Manning L.S., Davis M.R., Robinson B.V.S. Chemosensitivity and cytokine sensitivity of malignant mesothelioma. Cancer Chemother. Pharmacol. 28:1991;420-426.
6. Britton M. The epidemiology of mesothelioma. Semin. Oncol. 29(1):2002;18-25.
7. Burkhart C.A., Berman J.W., Swindell C.H.S., Horwitz S.B. Relationship between the structure of Taxol and other taxanes on induction of tumor necrosis factor-α gene expression and cytotoxicity. Cancer Res. 54:1994;5779-5782.
8. Caliandro R., Boutin C., Pero lM., Monnet I., Dabouis G., Guerin J.C., Le Chevalier T., Ruffie P. Phase II study of paclitaxel and cisplatinplatin in advanced pleural malignant mesothelioma. Lung Cancer. 18(Suppl. 1):1997;19.
9. Carbone M., Pass H.I., Rizzo P., Marinetti M., Di Muzio M., Mew D.J., Levine A.S., Procopio A. Simian virus 40-like DNA sequences in human pleural mesothelioma. Oncogene. 9(6):1994;1781-1790.
10. Carbone M., Rizzo P., Grimlay P.M., Procopio M., Mew D.J., Shridhar V., de Bartolomeis A., Esposito V., Giuloiano M.T., Steinberg S.M., Levine A.S., Giordano A., Pass H.I. Simian virus - 40 large-T antigen binds p53 in human mesotheliomas. Nat. Med. 3(8):1997;908-912.
11. Chahinian A.P., Antman K., Boutsou J., Corson J.M., Suzuki Y., Modeas C., Hernodon J.E., Aisner J., Ellison R.R., Leone I. Randomized phase II trial of cisplatinplatin with mitomycin or doxorubicin for malignant mesothelioma by the Cancer and Leukemia Group B. J. Clin. Oncol. 11:1993;1559-1565.
12. Cicala C., Pompetti F., Carbone M. SV40 induces mesothelioma in hamsters. Am. J. Pathol. 142(5):1993;1524-1533.
13. Craighead J.E., Mossman B.T. The pathogenesis of asbestos related disease. New Engl. J. Med. 306:1982;1446-1455.
14. Darzynkiewicz Z., Bruno S., Del Bino G. Features of apoptotic cells measured by flow cytometry. Cytometry. 13:1992;795-808.
15. de Cupis A., Noonan D., Pirani P., Ferrera A., Clerico L., Favoni R.E. Comparison between novel steroidal-like and conventional nonsteroidal antioestrogens in inhibiting oestradiol- and IGF-I-induced proliferation of human breast cancer-derived cells. Br. J. Pharmacol. 116:1995;2391-2400.
16. Dong H., Buard A., Renier A., Levy F., Saint-Etienne I., Jaurand M.C. Role of the oxygen derivatives in the cytotoxicity and DNA damage produced by asbestos on rat pleural mesothelial cells in vitro. Carcinogenesis. 15:1994;1251-1255.
17. Favoni R.E., de Cupis A., Bruno S., Yee D., Ferrera A., Pirani P., Costa A., Decensi A. Modulation of the insulin like-growth factor-I system by N-(4hydroxyphenyl)-retinamide in human breast cancer cell lines. Br. J. Cancer. 77:1998;2138-2147.
18. Fizazi K., John W.J., Vogelzang N.J. The emerging role of antifolates in the treatment of malignant pleural mesothelioma. Semin. Oncol. 29(1):2002;77-81.
19. Formelli F., Clerici M., Campa T., Mauro M.G., Magni A., Mascotti G., Moglia D., De Palo G., Costa A., Veronesi U. Five-years administration of fenretinide: pharmacokinetics and effects on plasma retinol concentrations. J. Clin. Oncol. 11:1993;2036-2046.
20. Gelmon K. The taxoids: Paclitaxel and Docetaxel. Lancet. 344:1994;1267-1272.
21. Girling D.J., Muers M.F., Quian W., Lobban D. Multicenter randomized controlled trial of the management of unresectable malignant mesothelioma proposed by British Thoracic Society and the British Medical Research Council. Semin. Oncol. 29(1):2002;97-101.
22. Hill B.T., Whelan R.D.H., Shellard S.A., Mcclean S., Hosking I.K. Differential cytotoxic effects of docetaxel in a range of mammalian tumor cell lines and certain drug resistant sublines in vitro. Invest. New Drugs. 12:1994;169-181.
23. Houghton P.J., Cheshire P.J., Hallman J.C., Bissery M.C., Mathieu-Boue A., Houghton J.A. Therapeutic efficacy of the topoisomerase-inhibitor7-ethyl-10-[4-(1-piperidine)-1-piperidine]- carbonyloxy-camptothecin against human tumor xenografts: lack of cross-resistance in vivo in tumors with acquired resistance to the topoisomerase I inhibitor 9-dimethylaminomethyl-10-hydroxycamptothecyn. Cancer Res. 53:1993;2823-2829.
24. Huang P., Plunkett W. Induction of apoptosis by gemcitabine. Semin. Oncol. 22(Suppl. 11):1995;19-25.
25. Jensen C.G., Jensen L.C., Rieder C.L., Cole R.W., Ault J.G. Long crocidolite asbestos fibers cause polyploidy by sterically blocking cytokinesis. Carcinogenesis. 17:1996;2013-2021.
26. Ke Y., Reddel R.R., Gerwin B.I., Reddel H.K., Sommers A.N.A., McMenamin M.G., LaVeck M.A., Stahel R.A. Establishment of a human in vitro mesothelial cell model system for investigating mechanisms of asbestos-induced mesothelioma. Pathology. 134:1989;979-991.
27. Kindler H.L. Malignant pleural mesothelioma. Curr. Treatm. Opt. Oncol. 1(4):2000;313-326.
28. Kindler H.L., van Meerbeeck J.P. The role of gemcitabine in the treatment of malignant mesothelioma. Semin. Oncol. 29(1):2002;70-76.
29. Knuuttila A., Ollikainen T., Halme M., Mali P., Kivisaari L., Linnainmaa K., Jekunen A., Mattson K. Docetaxel and irinotecan (CPT-11) in the treatment of malignant pleural mesothelioma: a feasibility study. Anticancer Drugs. 11(4):2000;257-261.
30. Leid M., Kastner P., Chambon P. Multiplicity generates diversity in the retinoic acid signalling pathways. Trends Biochem. Sci. 17:1992;427-433.
31. Liu J.Y., Morris G.F., Lei W.H., Hart C.E., Lasky J.A., Brody A.R. Rapid activation of PDGF-A and -B expression at sites of lung injury in asbestos exposed rats. Am. J. Respir. Cell Mol. Biol. 17:1997;129-140.
32. Loprevite M., Favoni R.E., de Cupis A., Pirani P., Merlo F., Grossi F., Ardizzoni A. Pre-clinical evaluation of new antineoplastic agents in NSCLC cell lines: evidence of histological subtype-dependent cytotoxicity. Int. J. Oncol. 15:1999;787-792.
33. Lotan R. Retinoid and apoptosis: implications for cancer chemoprevention and therapy. J. Natl. Cancer Inst. 87:1995;1655-1667.
34. Lubrasch O. Endothel. Ergeb. Allg. Pathol. 2:1895;592.
35. Martin S.J., Reutelingsperger C.P., McGahon A.J., Rader J.A., Vanschier C., Laface D.M., Green D.R. Early redistribution of plasma membrane phosphatidylserine is a general feature of apoptosis regardless of the initiating stimulus: inhibition by overexpression of Bcl-2 and Abl. J. Exp. Med. 182:1995;1545-1556.
36. McLaren B.R., Robinson B.W., Lake R.A. New chemotherapeutics in malignant mesothelioma: effects on cell growth and IL-6 production. Cancer Chemother. Pharmacol. 45:2000;502-508.
37. Min Lee J., Bruckner H.W., Szrajer L., Brenne U., Schindelheim G., Andreotti P.E. Taxol inhibits growth of mesothelioma xenografts. Anticancer Res. 15:1995;693-696.
38. Mintzer D.M., Kelsen D., Frimmer D., Heelan R., Gralla R. Phase II trial of high dose cisplatinplatin in patients with malignant mesothelioma. Cancer Treat. Rep. 69:1985;711-712.
39. Mossman B.T., Kamp D.W., Weitzman S.A. Mechanism of carcinogenesis and clinical features of asbestos-associated cancers. Cancer Investig. 14:1996;466-480.
40. Nakano T., Chahinian A.P., Shinjo M., Togawa N., Tonomura A., Miyake M., Ninomiya K., Yamamoto T., Higashino K. Cisplatinplatin in combination with irinotecan in the treatment of patients with malignant pleural mesothelioma. Cancer. 85:1999;2375-2384.
41. Nicoletti I., Migliorati G., Pagliacci M.C., Grignani F., Riccardi C. A rapid and simple method for measuring thymocyte apoptosis by propidium iodide staining and flow cytometry. J. Immunol. Methods. 139:1991;271-279.
42. Nowak A.K., Lake R.A., Kindler H.L., Robinson B.W. New approaches for mesothelioma: biologics, vaccines, gene therapy, and other novel agents. Semin. Oncol. 29(1):2002;82-96.
43. Olah E., Csokay B., Prajda N., Kote-Jarai Z., Yeh A.Y., Weber G. Molecular mechanisms in the antiproliferative action of taxol and tiazofurin. Anticancer Res. 16:1996;2469-2478.
44. Ollikainen T., Knuuttila A., Suhonen S., Taavitsainen M., Jekunen A., Mattson K., Linnainmaa K. In vitro sensitivity of normal human mesothelial and malignant mesothelioma cell lines to four new chemotherapeutic agents. Anticancer Drugs. 11(2):2000;93-99.
45. Ong S.T., Vogelzang N.J. Chemotherapy in malignant pleura mesothelioma: a review. J. Clin. Oncol. 14:1996;1007-1017.
46. Orengo A.M., Spoletini I., Procopio A., Favoni R.E., de Cupis A., Ardizzoni A., Castagneto B., Ribotta M., Betta P.G., Ferrini S., Mutti L. Establishment of four new mesothelioma cell lines: characterization by ultrastructural and immunophenotypic analysis. Eur. Respir. J. 13:1999;527-534.
47. Oridate N., Lotan D., Xu x.-C., Hong W.K., Lotan R. Differential induction of apoptosis by all-trans retinoic acid and N-(4-hydroxyphenyl)retinamide in human head and neck squamous cell carcinoma cell lines. Clin. Cancer Res. 2:1996;855-863.
48. Peto J., Decarli A., La Vecchia C., Levi F., Negri E. The European mesothelioma epidemic. Br. J. Cancer. 79:1999;666-672.
49. Plunkett W., Huang P., Xu y.-Z., Heinemann V., Grunewald R., Gandhi V. Gemcitabine: metabolism, mechanism of action, and self-potentiation. Semin. Oncol. 22(Suppl. 11):1995;3-10.
50. Ponzoni M., Bocca P., Chiesa V., Decensi A., Pistosi V., Raffaghello L., Rozzo C., Montaldo P.G. Differential effects of N-(4-hydroxyphenyl)retinamide and retinoic acid on neuroblastoma cells: apoptosis versus differentiation. Cancer Res. 55:1995;853-861.
51. Schmitter D., Lauber B., Fagg B., Stahel R.A. Hematopoietic growth factors secreted by seven human pleural mesothelioma cell lines: interleukin-6 production is a common feature. Int. J. Cancer. 51:1992;296-301.
52. Singhal S., Kaise L.R. Malignant mesothelioma: options for management. Surg. Clin. North Am. 82(4):2002;797-831.
53. Slichenmayer W.J., Rowinsky E.K., Donehower R.C., Kaufmann S.H. The current status of Camptothecin analogues as antitumor agents. J. Natl. Cancer Inst. 85:1993;275-291.
54. Smythe W.R. Current therapy for malignant mesothelioma. Curr. Oncol. Rep. 4(4):2002;305-313.
55. Testa J.R., Carbone M., Hirvonne A., Khalili K., Krynska B., Linnainmaa K., Pooley F.D., Rizzo P., Rusch V., Xiao G.H. A multi-institutional study confirms the presence and expression of simina virus-40 in human malignant mesotheliomas. Cancer Res. 58(20):1998;4505-4509.
56. Topov J., Kolev K. Cytology of experimental mesotheliomas induced with crocidolite asbestos. Acta Cytol. 31:1987;369-373.
57. Van Meerbeeck J.P., Baas P., Bebruyne C., Groen H.J., Manegold C., Ardizzoni A., Gridelli C., Van Marck E.A., Lentz M., Giaccone G. A phase II study of gemcitabine in patients with malignant pleural mesothelioma. European Organization for Research and Treatment of Cancer Lung Cancer Cooperative Group. Cancer. 85:1999;2577-2582.
58. Wieseman L.R., Markham A. Irinotecan, a review of its pharmacological properties in the management of advanced colorectal cancer. Drugs. 52:1996;606-623.
59. Yegles M., Saint-Etienne L., Renier A., Janson X., Jaurand M.C. Induction of metaphase and anaphase/telophase abnormalities by asbestos fibers in rat pleural mesothelial cells in vitro. Am. J. Respir. Cell Mol. Biol. 9:1993;186-191.
60. Zellos L.S., Sugarbaker D.J. Diffuse malignant mesothelioma of the pleural space and its management. Oncology (Huntingt.). 16(7):2002;907-913.
61. Zidar B.L., Green S., Pierce H.I., Roach R.W., Balcerzack S.P., Militello L. A phase I evaluation of cisplatinplatin in unresectable diffuse malignant mesothelioma: a Southwest Oncology Group study. Invest. New Drugs. 6:1988;223-226.
62. Zou C.-P., Kurie J.M., Lotan D., Zou C.-C., Hong W.K., Lotan R. Higher potency of N-(4-hydroxyphenyl)retinamide than all-trans-retinoic acid in induction of apoptosis in non-small cell lung cancer cell lines. Clin. Cancer Res. 4:1998;1345-1355.